---
title: "US FDA approves Insmed's lung disease drug"
description: "The U.S. FDA has approved Insmed's oral drug, Brinsupri, for treating non-cystic fibrosis bronchiectasis, marking it as the first treatment for this chronic lung disease. This condition affects 350,00"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252713806.md"
published_at: "2025-08-12T15:47:04.000Z"
---

# US FDA approves Insmed's lung disease drug

> The U.S. FDA has approved Insmed's oral drug, Brinsupri, for treating non-cystic fibrosis bronchiectasis, marking it as the first treatment for this chronic lung disease. This condition affects 350,000 to 500,000 adults in the U.S. Brinsupri functions by inhibiting inflammatory enzymes in white blood cells, reducing lung damage caused by overactive immune responses.

Aug 12 (Reuters) - The U.S. Food and Drug Administration has approved Insmed’s (INSM.O) oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.

Insmed’s drug, branded as Brinsupri, targets non-cystic fibrosis bronchiectasis, a chronic lung condition characterized by permanently damaged airways, leading to persistent cough and excessive mucus production.

It affects 350,000 to 500,000 adults in the U.S., according to the American Lung Association.

Brinsupri works by blocking certain inflammatory enzymes in the white blood cells, preventing them from becoming overactive and damaging the lungs.

### Related Stocks

- [INSM.US - Insmed](https://longbridge.com/en/quote/INSM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Insmed（納斯達克代碼：INSM）的首席執行官出售了價值 3,247,335.00 美元的股票 | Insmed 首席執行官 William Lewis 於 1 月 12 日出售了 19,215 股公司股票，交易金額為 3,247,335 美元，減少了 5.89% 的持股比例。出售後，他持有 306,891 股，估值約為 5186 萬美元 | [Link](https://longbridge.com/en/news/272531097.md) |
| Insmed 首席醫療官 Martina Flammer 報告出售普通股 | Insmed Inc. 首席醫學官 Martina Flammer, M.D. 報告了普通股的出售。完整的文件可通過提供的鏈接獲取。此消息由公共技術生成，僅供信息參考，不應被視為財務、投資或法律建議。Insmed Inc. 對於 2026  | [Link](https://longbridge.com/en/news/272456905.md) |
| 根據最近的 SEC 文件，Insmed 的一位內部人士出售了價值 351,341 美元的股票 | 根據最近的 SEC 文件，Insmed 內部人士出售了價值 351,341 美元的股份 | [Link](https://longbridge.com/en/news/272458780.md) |
| 根據最近的 SEC 文件，Insmed 的一位內部人士出售了價值 3,247,349 美元的股票 | 根據最近的 SEC 文件，Insmed 內部人士出售了價值 3,247,349 美元的股份 | [Link](https://longbridge.com/en/news/272458799.md) |
| Insmed 的高管們悄然兑現了數百萬美元的股票收益 | Insmed 的高管，包括首席執行官 William Lewis 和首席財務官 Sara Bonstein，最近出售了其股票持有的重大部分，總金額超過 300 萬美元。這一內部出售發生在 Insmed 的股價因 Brinsupri 的第二階 | [Link](https://longbridge.com/en/news/272012630.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.